American tech entrepreneur and venture capitalist Bryan Johnson recently announced he has autoimmune gastritis. “My stomach is eating itself,” said the anti-aging enthusiast and creator of Project Blueprint. For more than a decade, Johnson has spent approximately $2 million per year tracking nearly every measurable biological parameter. He has a team of physicians and undergoes continuous multiomics testing. And still, a chronic autoimmune disease was silently destroying his gastric parietal cells for at least 11 years before it was identified.
The public commentary on Johnson’s condition fell into two predictable camps. The conventional medical view: autoimmune gastritis is an organ-level diagnosis; manage the nutrient deficiencies and monitor for gastric cancer risk—nothing more to be done. The integrative commentary (including a piece by Sayer Ji that is worth reading): vaccine-related molecular mimicry is a potential upstream trigger, citing a published case report of the exact clinical triad Johnson presents in the context of mRNA vaccination.
Both camps are reading the symptom list. Neither is reading the terrain.
This article is a Systems Homeostasis analysis of Bryan Johnson’s case—it is not a diagnosis or a clinical opinion about a man whose chart and full medical history is not publicly available. Rather, this discussion is a demonstration of what the upstream signal architecture looks like when you apply the governing framework: Response = Input x Terrain.
What Autoimmune Gastritis Actually Is
Autoimmune gastritis is not a stomach disease. It is a systemic immune governance failure expressed at the gastric mucosa.
The mechanism: autoantibodies — specifically anti-parietal cell antibodies (APCA) and anti-intrinsic factor antibodies — attack the H+/K+-ATPase proton pump on gastric parietal cells. Over time, parietal cell mass declines, gastric acid production falls, intrinsic factor secretion is lost, and the absorption of iron and B12 becomes progressively impaired. The clinical presentation — low ferritin, eventual B12 deficiency, pernicious anemia, neurological sequelae — is not the disease. It is the downstream consequence of a decade or more of silent immune-mediated destruction at the gastric mucosa.
Johnson’s anti-parietal cell antibody titer was confirmed at 103 U/mL against an upper reference limit of 20 U/mL — five times the ceiling. Biopsy confirmed early atrophy confined to the acid-producing lining. Eleven years of flagged low ferritin was the only surface signal.
The question Systems Homeostasis asks is not: what is destroying the parietal cells? The question is: what terrain made that immune governance failure possible, and what inputs converged to produce it?
Johnson’s documented protocol includes over 111 compounds daily. The hepatic processing burden alone creates a demand profile that is not clinically neutral. Some of those compounds are immune-modulating. The gut microbiome, which is the primary regulator of mucosal immune tone, is under continuous chemical influence from a protocol that no clinical trial has ever tested as an integrated system.
Bryan Johnson’s Terrain: What Was Already in Place
Before a single trigger is considered, the terrain needs to be read.
Johnson was diagnosed with autoimmune hypothyroidism — Hashimoto’s thyroiditis — at age 21. This is the most important single fact in the clinical picture and the one that contextualizes everything that followed. He did not develop autoimmune gastritis in isolation. He has an established autoimmune terrain — a system in which immune tolerance at mucosal surfaces has already demonstrated a failure pattern — that predates his biohacking protocol by decades.
The connection between thyroid and gastric autoimmunity is well-documented: people with autoimmune thyroid disease are significantly more likely to be diagnosed with autoimmune gastritis. This is formalized clinically as thyrogastric syndrome — the triad of autoimmune thyroid disease, autoimmune gastritis, and iron deficiency anemia. Johnson himself described his situation as “never one problem. It was three, linked to one another: the iron deficiency, the autoimmune gastritis driving it, and the autoimmune thyroid disease alongside it.”
That framing is closer to Systems Homeostasis thinking than most of the commentary that followed — but it still doesn’t go upstream far enough. The three linked conditions are themselves downstream of a shared upstream failure: immune governance at the mucosal interface. The terrain that produced Hashimoto’s at 21 is the same terrain that produced autoimmune gastritis over the following two-plus decades.
The Inputs: What the Signal Architecture Shows
The principle that Systems Homeostasis applies is that root causes are rarely singular. What we find in almost every complex chronic presentation is a convergence of upstream inputs into a terrain that became permissive for the downstream expression. Johnson’s case is a textbook demonstration.
Input 1:
Established autoimmune predisposition. Hashimoto’s at 21 establishes the baseline terrain. An immune system that has already demonstrated a failure of self-tolerance at the thyroid carries a systemic predisposition toward further autoimmune expression. This is not a causal relationship between thyroid and gastric autoimmunity; it is a shared upstream immune governance architecture that makes both expressions more probable. The terrain was permissive before any other input arrived.
Input 2:
Chronic caloric restriction as a multi-system stressor. Johnson’s documented caloric intake is approximately 1,977 calories. For a man of his body composition, muscle mass, and activity level, this represents a sustained energy deficit that constitutes a chronic physiological stressor independent of any psychological stress architecture. The HPA axis reads an energy deficit as a threat signal — cortisol rises not from psychological pressure but from substrate insufficiency. Enterocyte turnover is energetically expensive; in a chronic deficit, mucosal repair is deprioritized, tight junction maintenance is compromised, and secretory IgA production — the primary immunological defense at mucosal surfaces — declines. Regulatory T cell function, which is the active mechanism of mucosal immune tolerance, is energy-demanding and degrades under chronic restriction. Parietal cells are among the most mitochondria-dense cells in the body, requiring exceptional ATP output to maintain their proton gradient. They are disproportionately vulnerable to chronic energy insufficiency.
Input 3:
Ultra-high supplement loading. Johnson’s documented protocol includes over 111 compounds daily. The hepatic processing burden alone creates a demand profile that is not clinically neutral. Some of those compounds are immune-modulating. The gut microbiome, which is the primary regulator of mucosal immune tone, is under continuous chemical influence from a protocol that no clinical trial has ever tested as an integrated system. The aggregate terrain effect of 111+ compounds operating simultaneously has never been characterized — and in a system with established autoimmune predisposition and declining mucosal repair capacity, that effect is not trivially benign.
Input 4:
Predominantly vegetarian diet and iron absorption. Non-heme iron requires gastric acid for reduction from Fe3+ to the absorbable Fe2+ form. In a system where parietal cell function was already declining — silently, for years — iron absorption from a predominantly plant-based diet was doubly compromised: low dietary heme iron supply meeting a progressively acid-insufficient gastric environment. The ferritin signal that appeared eleven years ago was not just a dietary insufficiency. It was the earliest measurable output of a convergent failure.
Input 5:
H. pylori — the most established upstream trigger. H. pylori expresses antigens — specifically the CagA protein and urease subunits — with structural homology to H+/K+-ATPase, the primary antigen in autoimmune gastritis. Molecular mimicry between H. pylori antigens and gastric parietal cell antigens is the most established mechanistic pathway for initiating anti-parietal cell antibody production. Johnson’s H. pylori status has not been publicly disclosed. It is the most clinically important data point in the entire upstream picture — and the least discussed in the current commentary. A man with Hashimoto’s, declining gastric acid, and iron malabsorption over eleven years warrants a thorough H. pylori workup including virulence factor typing.
Input 6:
Vaccine-related molecular mimicry — one input among several. A published case report describes a patient with the exact triad Johnson presents — Hashimoto’s, pernicious anemia, and autoimmune atrophic gastritis — in the context of SARS-CoV-2 vaccination. New-onset Graves’ disease and thyroiditis after mRNA vaccination are documented in the case report literature, with spike-thyroid molecular mimicry named as the mechanism. The mechanistic hypothesis is legitimate. What the evidence supports is this: in a system already carrying autoimmune predisposition, with declining mucosal repair capacity and impaired regulatory T cell function — a molecular mimicry trigger, from any source, finds a terrain that is ready to respond to it. The trigger lands differently depending on the terrain it arrives into.
Autoimmune disease is not a thing that happens to a body. It is what a terrain produces when immune governance fails across enough systems simultaneously to remove the active suppression of autoreactive immune cells. Low ferritin was not a dietary inconvenience — it was the surface signal of a convergent upstream failure that the data was not being read to find.
What the Convergence Model Shows
Johnson arrived at autoimmune gastritis through a convergence of inputs — not any one of which is sufficient alone, and not any one of which is the single root cause. An established autoimmune terrain predating his biohacking protocol by decades. A chronic energy deficit generating HPA activation and depleting mucosal repair resources across at least five systems. A supplement load whose integrated terrain effect has never been characterized. A dietary pattern that was already compromising iron absorption before parietal cell atrophy arrived. An unknown H. pylori history that represents the most clinically established upstream trigger for exactly this condition. And possibly — legitimately, not certainly — a molecular mimicry contribution from vaccine antigens arriving into a terrain that was already permissive.
Response = Input x Terrain
The response here was autoimmune gastritis. The terrain was built over decades — some of it genetic, some of it dietary, some of it iatrogenic, some of it the unintended consequence of an extreme optimization protocol applied to a system that was already carrying autoimmune predisposition.
This is not a criticism of Bryan Johnson. He is doing something genuinely valuable — documenting his biology publicly, refusing to accept the standard of care verdict, and pursuing experimental immune therapies that may ultimately benefit far more people than himself. His framing of the situation as “never one problem — it was three, linked to one another” shows more systems thinking than most of the gastroenterology commentary that followed. But the three linked conditions he identified are themselves downstream. The upstream architecture — the terrain that made all three possible — is what Systems Homeostasis is designed to read.
What the Intervention Architecture Should Look Like
Without Johnson’s full clinical picture — cortisol diurnal curve, complete hormone panel, gut microbiome, mucosal barrier markers, H. pylori status with virulence factor typing, full metabolic panel — any intervention sequence is provisional. But the signal hierarchy is readable from what is publicly known.
The intervention sequence does not begin with immune suppression or experimental CAAR-T therapy. It begins with terrain correction. First: establish what is driving the immune governance failure — H. pylori status with virulence typing, complete autoimmune panel, gut barrier integrity assessment (zonulin, sIgA, DAO/histamine ratio). Second: address the energy architecture — chronic caloric restriction in a catabolic system with autoimmune predisposition is a terrain degrader, not a longevity strategy. Third: rationalize the supplement protocol — 111+ compounds is an experiment without controls; identifying the immune-modulating compounds and hepatic demand contributors is a prerequisite for measurable terrain correction. Fourth: support regulatory T cell function directly — Vitamin D3 optimized to 60–80 ng/mL (regulatory T cell induction requires higher 25(OH)D concentrations than the standard 40 ng/mL target), butyrate, and Akkermansia muciniphila pasteurized. Fifth — and only fifth — consider the experimental immune interventions. Antigen-specific tolerance strategies and regulatory T cell therapy are legitimate frontier approaches, but applied to a terrain that hasn’t been corrected upstream, they are solving the wrong problem at the wrong level.
The Lesson That Isn’t Being Drawn
The most expensive, most data-rich health optimization protocol on the planet produced eleven years of an unread signal because the framework being applied was looking for problems in isolation rather than reading a signal architecture.
Autoimmune disease is not a thing that happens to a body. It is what a terrain produces when immune governance fails across enough systems simultaneously to remove the active suppression of autoreactive immune cells. Low ferritin was not a dietary inconvenience — it was the surface signal of a convergent upstream failure that the data was not being read to find.
That is the lesson. And it is precisely the lesson Systems Homeostasis exists to address.
About the author: Rob Lamberton, BSc, FNTP, FDN-P(c), is a formulation scientist and systems-based clinical consultant, and the developer of the Systems Homeostasis framework and the Formulation Intelligence Engine. He is based in Thailand and can be reached at rob@roblamberton.com.
